Patients receiving long-term opioid therapy for chronic pain and interested in tapering their opioid dose were randomly assigned to a 22-week taper support intervention (psychiatric consultation, opioid dose tapering, and 18 weekly meetings with a physician assistant to explore motivation for tapering and learn pain self-management skills) or usual care (N=35). Assessments were conducted at baseline and 22 and 34 weeks after randomization. Using an intention-to-treat approach, we constructed linear regression models to compare groups at each follow-up. At 22 weeks, adjusted mean daily morphine-equivalent opioid dose (MED) in the past week (primary outcome) was lower in the taper support group, but this difference was not statistically significant (adjusted mean difference = −42.9 mg; 95% CI: −92.42, 6.62; p= 0.09). Pain severity ratings (0–10 NRS) decreased in both groups at 22 weeks, with no significant difference between groups (adjusted mean difference = −0.68; 95% CI: −2.01, 0.64; p = 0.30). The taper support group improved significantly more than usual care in self-reported pain interference, pain self-efficacy, and prescription opioid problems at 22 weeks (all p-values <0.05). This taper support intervention is feasible and shows promise in reducing opioid dose while not increasing pain severity or interference. [ClinicalTrials.gov Identifier: NCT01883882]